A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWERCSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

DSpace Repository

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWERCSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Author: Hughes, Brett G. M.; Guminski, Alexander; Bowyer, Samantha; Migden, Michael R.; Schmults, Chrysalyne D.; Khushalani, Nikhil I.; Chang, Anne Lynn S.; Grob, Jean-Jacques; Lewis, Karl D.; Ansstas, George; Day, Fiona; Ladwa, Rahul; Stein, Brian N.; Couselo, Eva Munoz; Meier, Friedegund; Hauschild, Axel; Schadendorf, Dirk; Basset-Seguin, Nicole; Modi, Badri; Dalac-Rat, Sophie; Dunn, Lara A.; Flatz, Lukas; Mortier, Laurent; Guegan, Sarah; Heinzerling, Lucie M.; Mehnert, Janice M.; Trabelsi, Sabiha; Soria-Rivas, Ainara; Stratigos, Alexander J.; Ulrich, Claas; Wong, Deborah J.; Beylot-Barry, Marie; Bossi, Paolo; Sanchez, Cristina Buges; Chandra, Sunandana; Robert, Caroline; Russell, Jeffery S.; Silk, Ann W.; Booth, Jocelyn; Yoo, Suk-Young; Seebach, Frank; Lowy, Israel; Fury, Matthew G.; Rischin, Danny
Tübinger Autor(en):
Flatz, Lukas
Published in: Journal of The American Academy of Dermatology (2025), Bd. 92, H. 1, S. 68-77
Verlagsangabe: New York : Mosby - Elsevier
Language: English
Full text: http://dx.doi.org/10.1016/j.jaad.2024.06.108
ISSN: 0190-9622
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)